Ken Griffin Entera Bio Ltd. Put Options Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$1.48 - $2.14 $148 - $214	100 New	100 $0
Q3 2023 Nov 14, 2023	BUY	$0.6 - $0.88 $60 - $88	100 New	100 $0
Q1 2023 May 15, 2023	BUY	$0.83 - $1.44 $581 - $1,008	700 Added 233.33%	1,000 $1,000
Q4 2022 Feb 14, 2023	BUY	$0.5 - $1.05 $150 - $315	300 New	300 $0

5.34M

2.6K

100

Ticker ENTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,809,900
Market Cap $49.8M
Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.